Risperidone dose for schizophrenia (Q24240095)

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Extrapyramidal symptoms in patients treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Effect of Risperidone on Hostility in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Dose response and dose equivalence of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Survey on the pharmacodynamics of the new antipsychotic risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

21 January 2018

Risperidone: a review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Haloperidol dose for the acute phase of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

Five factor model of schizophrenia: replication across samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

The SKT--a short cognitive performance test for assessing deficits of memory and attention.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

1 reference

7 January 2021

Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

Risperidone: clinical development: north American results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

Relatives of patients with severe psychotic disorders: factors that influence contact frequency. Report from the UK700 trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021

A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007474.PUB2

7 January 2021